Oversight Committee Pushes Insurers, PBMs On Contraceptive Coverage

The House oversight committee is the latest Congressional panel to press insurers and pharmacy benefit managers (PBMs) about their compliance with the Affordable Care Act’s mandate to cover all FDA-approved contraceptives with no cost-sharing following reports that companies are shirking the requirements. House oversight committee Chair Carolyn Maloney (D-NY) sent letters to nine PBMs and insurers with a series of questions on their coverage policies and demand responses by June 9. “I am deeply troubled by reports that health plans...
Article Type: 
Tags: 
Site Name: 
InsideHealthPolicy.com
CMS Issue: 
Inside CMS - 06/02/2022
CMS Volume: 
Vol. 25, No. 22
HEA Issue: 
Health Exchange Alert Weekly Report - 06/01/2022
HEA Volume: 
Vol. 10, No. 22
Author: 

New NASEM Committee To Tackle Pediatric Workforce Shortages

A new committee of the National Academies of Sciences, Engineering, and Medicine, in partnership with the Association of Medical School Pediatric Department Chairs, has begun assessing solutions to a significant shortage of pediatric health care workers, especially pediatric subspecialists, which the committee said will impede pediatric patients from receiving quality care and will decrease the field’s overall expertise in the long term. An overall health care workforce shortage has concerned some experts for years, and pandemic-related retirements and resignations drove...
Article Type: 
Site Name: 
InsideHealthPolicy.com
CMS Issue: 
Inside CMS - 06/02/2022
CMS Volume: 
Vol. 25, No. 22
Author: 

CMS To Cut Medicare Part B 2023 Premiums After Lower Aduhelm Costs

HHS plans to lower Medicare Part B premiums in 2023 to compensate for this year’s lower-than-expected spending after CMS reports it overestimated the costs and patient use of the Alzheimer’s drug Aduhelm when calculating this year’s monthly premiums, which went up $21.60 for 2022 in part to pay for the controversial drug. But because of the difficulties with changing premiums mid-year, HHS has opted to lower the 2023 premiums for beneficiaries to make up for the overly high costs in...
Article Type: 
Tags: 
Site Name: 
InsideHealthPolicy.com
CMS Issue: 
Inside CMS - 06/02/2022
CMS Volume: 
Vol. 25, No. 22

Senate User Fee Bill Speeds FDA’s Therapeutic Equivalence Decisions

Senate health committee Chair Patty Murray (D-WA) and ranking Republican Richard Burr (R-NC) on Friday (May 27) introduced their user fee bill with some changes from the draft version, including a new measure that aims to shorten FDA’s decision-making around whether 505(b)(2) drugs may be automatically substituted at the pharmacy for the brand drugs they reference. The bill also would require FDA to quickly finish its over-the-counter hearing aid rule and provide Congress with more information about its inspection activities...
Article Type: 
Site Name: 
InsideHealthPolicy.com
FDA Issue: 
FDA Week - 06/03/2022
FDA Volume: 
Vol. 28, No. 22
Author: 
Secondary Author(s): 

Consumer Advocates Worry About Phone Scams In Post-PHE Renewals

A group of consumer protection advocates are concerned the Federal Communications Commission could open the door to scam calls and telemarketers if it gives too much flexibility to CMS, states and contractors who want to be able to call or text Medicaid and Children’s Health Insurance Program beneficiaries about their renewals once the public health emergency ends without the fear of violating the Telephone Consumer Protection Act. The advocates urge FCC to make sure such a contact policy includes appropriate...
Article Type: 
Tags: 
Site Name: 
InsideHealthPolicy.com
CMS Issue: 
Inside CMS - 06/02/2022
CMS Volume: 
Vol. 25, No. 22
HEA Issue: 
Health Exchange Alert Weekly Report - 06/01/2022
HEA Volume: 
Vol. 10, No. 22

Senate Accelerated Approval Reforms Mirror House Bill With One Exception

The Senate FDA user fee bill that was introduced Friday (May 27) includes accelerated approval reforms that mirror the House user fee bill, with the exception of a new measure in the Senate bill to create an “intra-agency coordinating council” to ensure uniform usage of accelerated approvals. The draft legislation that Senate health committee Chair Patty Murray (D-WA) and ranking GOP member Richard Burr (NC) released May 17 did not include changes to FDA’s accelerated approval path, which prompted lobbying...
Article Type: 
Site Name: 
InsideHealthPolicy.com
IDP Issue: 
Inside Drug Pricing - 05/30/2022
IDP Volume: 
Vol. 5, No. 22
Author: 

Rosen, Romney Introduce Bill To Research Nonprofit Pharma Sector

Sens. Jacky Rosen (D-NV) and Mitt Romney (R-UT) introduced legislation Friday (May 27) that would direct the Government Accountability Office (GAO) to study the impact of nonprofit generic drug makers on the drug industry and the barriers to their prominence. The bill is meant to help nonprofit generic drug makers, but it’s a far cry from Rosen’s previous bill, which would make it easier for them to acquire nonprofit tax-exempt status, provide them grants and low-interest loans, and waive FDA...
Article Type: 
Site Name: 
InsideHealthPolicy.com
IDP Issue: 
Inside Drug Pricing - 05/30/2022
IDP Volume: 
Vol. 5, No. 22
Author: 






Pages

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.